Kangstem Biotech Co Ltd

217730

Company Profile

  • Business description

    Kangstem Biotech Co Ltd develops technology to isolate the non-hematological system stem cell with conversion and purity from the cord blood and to culture large quantity. Its Furestem therapies include Furestem-AD, Furestem-RA and Furestem-CD. Its businesses include cord blood-derived stem cell therapy business; cord blood-derived stem cell conditioned media business; and stem cell culture media business.

  • Contact

    512 Teheran-ro, Gangnam-gu
    17th Floor, Sinan Building
    Seoul
    KOR

    T: +82 28881590

    http://www.kangstem.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    92

Stocks News & Analysis

stocks

Are small caps finally back?

Does renewed investor interest point to a structural shift in the underperforming factor?
stocks

Chart of the Week: Modest earnings growth at odds with overvalued bank shares

The latest update from our Industry Pulse report.
stocks

Solid start to fiscal 2026 for BHP

Production guidance is maintained by management.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,329.1050.900.55%
CAC 408,225.7818.910.23%
DAX 4024,207.7956.660.23%
Dow JONES (US)46,793.32202.910.44%
FTSE 1009,578.5763.570.67%
HKSE25,967.98186.210.72%
NASDAQ22,965.24224.840.99%
Nikkei 22548,641.61666.18-1.35%
NZX 50 Index13,377.1070.660.53%
S&P 5006,747.2947.890.71%
S&P/ASX 2009,032.8046.600.52%
SSE Composite Index3,922.418.650.22%

Market Movers